VivoSeq
Nephrology

Autosomal Dominant Polycystic Kidney Disease

39

Pipeline Programs↗

10

Active Trials↗

27

Companies Involved↗

Autosomal Dominant Polycystic Kidney Disease is a moderately active landscape with 39 programs across 27 companies. The most active players are Regulus Therapeutics Inc., GSK, AstraZeneca. 8 therapies are approved with 10 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

57/100

Pipeline Velocity

15/100

Mech. Concentration

12/100

Completion Rate

79/100

Attrition Rate

14/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

R

Regulus Therapeutics Inc.

2 programs

Phase 1GSK logo

GSK

1 program

Phase 1AstraZeneca logo

AstraZeneca

1 program

Phase 1Eli Lilly logo

Eli Lilly

2 programs

Phase 2P

Palladio Biosciences

1 program

Phase 2K

Kadmon, a Sanofi Company

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

90%

Small molecule

36 of 40 classified programs — the dominant modality here.

10%ALL OTHERSPeptide38%Protein / enzyme13%

Small molecule leads; the ring shows all 40 classified programs, each share of the total. Modality classified for 98% of 42 pipeline programs.

Analysis

Trial Status

49

clinical trials

Completed27 · 55%
Terminated7 · 14%
Recruiting5 · 10%
Unknown status5 · 10%
Active, not recruiting2 · 4%
Not yet recruiting2 · 4%
Other1 · 2%

Clinical Trials

Trial Activity

49 trials

A Study to Evaluate the Safety, Tolerability, and Effects on Blood and Urine Markers of Single Ascending Dose of GSK4771261 in Healthy Participants and Participants With Autosomal Dominant Polycystic Kidney Disease
Recruiting·GSK logoGSK·Phase 1·NCT06734234·84 enrolled
Safety, Tolerability and Pharmacokinetics of AZD1613 in Adults With Autosomal Dominant Polycystic Kidney Disease
Recruiting·AstraZeneca logoAstraZeneca·Phase 1·NCT07228364·40 enrolled
Trial of JMKX003142 in Participants With Rapidly Progressive Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Recruiting·JJemincare·Phase 2·NCT06800651·135 enrolled
A Study to Assess Adverse Events and Effectiveness of IntraVenous Infusions of ABBV-CLS-628 in Adult Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Recruiting·AbbVie logoAbbVie·Phase 2·NCT06902558·240 enrolled
Short-term Effects of an SGLT2 Inhibitor on Divalent Ions in Autosomal Dominant Polycystic Kidney Disease
Recruiting·—·Phase 2·NCT06435858·40 enrolled
Feasibility of Study of Empagliflozin in Patients With Autosomal Dominant Polycystic Kidney Disease
Active, not recruiting·UUniversity of Colorado, Denver·Phase 2·NCT05510115·50 enrolled
Study of Empagliflozin in Patients With Autosomal Dominant Polycystic Kidney Disease (EMPA-PKD)
Active, not recruiting·HHannover Medical School·Phase 4·NCT06391450·44 enrolled
Safety of RotigotiNe in Patients With Autosomal Dominant Polycystic Kidney Disease
Not yet recruiting·UUniversity Hospital, Rouen·Phase 2·NCT06291116·120 enrolled
Open Labeled , Randomized, Controlled, Crossover Trial on the Effect of a Carbohydrate Restricted Plant Dominant Diet on MCP-1 Mediated Inflammatory Signaling in Autosomal Dominant Polycystic Kidney Disease
Not yet recruiting·AAssaf-Harofeh Medical Center·Preclinical·NCT07651397·36 enrolled
Atorvastatin and Alkali Therapy in Patients With Autosomal Dominant Polycystic Kidney Disease
Enrolling by invitation·TTaipei Medical University Shuang Ho Hospital·Phase 2·NCT05870007·30 enrolled
A Study of RGLS4326 in Patients With Autosomal Dominant Polycystic Kidney Disease
Completed·RRegulus Therapeutics Inc.·Phase 1·NCT04536688·19 enrolled
Long Term Safety of Immediate-release Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease
Completed·Otsuka logoOtsuka·Phase 3·NCT02251275·1,803 enrolled
Adrenal Functions in Autosomal Dominant Polycystic Kidney Disease
Completed·IIstanbul University·N/A·NCT00598377·49 enrolled
Mineralocorticoid Antagonism and Endothelial Dysfunction in Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Completed·UUniversity of Colorado, Denver·Phase 3·NCT01853553·61 enrolled
8-Week Study of Tolvaptan Dose Forms in Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Completed·Otsuka logoOtsuka·Phase 2·NCT01451827·178 enrolled
Page 1 of 4

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)